Shares of biotechnology company CSL (ASX:CSL) increased as much as 1.73%, reaching A$250.61.

This marks their largest gain since August 30.

Analysts at Morgan Stanley opined that the execution of Patient Blood Management (PBM) might neutralize the competitive risk presented by injectafer generics for CSL.

PBM is a method employed in the treatment of surgical patients who necessitate blood transfusion.

The analysts project an earnings per share increase of approximately 16%, subsequently bolstered by opportunities for injectafer within PBS programs.

The brokerage’s 12-month price target for CSL is A$334 per share, 33% above the present level of A$252 per share.

As per LSEG data, the average analysts' rating mirrors a ‘Buy’ suggestion, with their median price target settled at A$325.

About 409,000 shares were traded, compared to the 30-day average volume of 755,322.

As of the last closing, the stock has declined 14.4% YTD.

CSL is a leading company in the biotechnology sector known for its wide range of plasma-derived and recombinant therapies.